Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: A double-blind, multicentre, randomized, dose-finding trial

British Journal of Dermatology

Volumn 152, Issue 6, 2005, Pages 1219-1227

  Gottlieb, Alice B ^a   Griffiths, C E M ^b   Ho, V C ^c   Lahfa, M ^d   Mrowietz, U ^e   Murrell, D F ^f   Ortonne, J P ^g   Todd, G ^h   Cherill, R ⁱ   Marks, I ⁱ   Emady Azar, S ⁱ   Paul, C F ⁱ  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adults; Oral; Pimecrolimus; Plaque type psoriasis; Randomized

Indexed keywords

ALEFACEPT; CALCINEURIN INHIBITOR; CLOBETASOL PROPIONATE; CYCLOSPORIN; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; METHOTREXATE; PIMECROLIMUS; PLACEBO; PSORALEN; RETINOID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BONE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLICULITIS; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSOMNIA; INTERVERTEBRAL DISK HERNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; OUTCOMES RESEARCH; PARESTHESIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PUVA; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN DISEASE; SKIN INFECTION; STATISTICAL ANALYSIS;

ABDOMINAL PAIN; ADULT; AGED; BLOOD GLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; SKIN; SLEEP INITIATION AND MAINTENANCE DISORDERS; STATISTICS; TACROLIMUS; TREATMENT OUTCOME;

EID: 21644486867     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06661.x     Document Type: Article

References (35)

1. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26:314-20.
2. Greaves MW, Weinstein GD. Treatment of psoriasis. N Enjl J Med 1995; 332:581-8.
3. Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med 1999; 107:595-605.
4. Krueger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient membership survey. Arch Dermatol 2001; 137:280-4.
5. Fortune DG, Main CJ, O'Sullivan TM et al. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997; 137:755-60.
6. De Boer O, Wakelkamp I, Pals S et al. Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin. Arch Dermatol Res 1994; 286:304-11.
7. Gottlieb AB, Lifshitz B, Fu SM et al. Expression of HLA-DR molecules by keratinocytes and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med 1986; 164:1013-28.
8. 389IL-2) suggests a primary immune, but not keratinocyte, pathogen basis. Nat Med 1995; 1:442-7.
9. Gottlieb AB. Immunopathogenesis of psoriasis. Arch Dermatol 1997; 133:781-2.
10. Baker BS, Fry L. The immunology of psoriasis. Br J Dermatol 1992; 126:1-9.
11. Griffiths CE, Voorhees JJ. Psoriasis, T cells and autoimmunity. J R Soc Med 1996; 89:315-19.
12. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 1:40-5.
13. Roenigk HH Jr, Auerbach R, Maibach H et al. Methotiexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38:478-85.
14. Paul C, Dubertret L. Etretinate and acitretin: strategy for use and long-term side effects. In: Psoriasis (Roenigk HH Jr, Maibach HI, eds), 3rd edn. New York: Marcel Dekker, 1998; 671-83.
15. Grossman RM, Chevret S, Abi-Rached J et al. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996; 132:623-9.
16. Stern RS, Laird N, Melski J et al. Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med 1984; 310:1156-61.
17. Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA follow-up study. J Natl Cancer Inst 1998; 90:1278-84.
18. Gottlieb AB, Bos JD. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol 2002; 105:105-16.
19. Grassberger M, Baumruker T, Enz A et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141:264-73.
20. Meingassner J, Grassberger M, Fahrngruber H et al. A potential new anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997; 137:568-76.
21. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981)-preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001; 20:233-41.
22. Mrowietz U, Graeber M, Bräutigam M et al. The novel ascomycin derivative SDZ ASM 981 is an effective anti-psoriatic compound when used topically under occlusion. Br J Dermatol 1998; 139:992-6.
23. Rappersberger K, Komar M, Ebelin ME et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002; 119:876-87.
24. Fredericksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157:238-44.
25. Maurer W, Hothorn LA, Lehmacher W. Multiple comparisons in drug clinical trials and preclinical assays: a-priori ordered hypotheses. In: Biometrie in der Chemisch-Pharmazeutischen Industrie: Testing Principles in Clinical, Preclinical Trials. Stuttgart: Gustav Fischer Verlag, 1995; 3-18.
26. Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmune, in patients with severe psoriasis. Br J Dermatol 1998; 139:88-95.
27. Gourishankar S, Jhangri GS, Tonelli M et al. Development of diabetes mellitus following kidney transplantation: a Canadian experience. Am J Transplant 2004; 4:1876-82.
28. Griffiths CEM, Clark CM, Chalmers RJ et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4:1-125.
29. Murray HE, Anhalt AW, Lessard R et al. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study. J Am Acad Dermatol 1991; 24:598-602.
30. Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporin in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349:658-65.
31. Fairlie C, Baldwin L, Year L et al. Bath PUVA: an effective treatment for psoriasis. Dermatol Nurs 1998; 10:285-9.
32. Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139:1627-32; discussion 1632.
33. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014-22.
34. Lebwohl M, Tyring SK, Hamilton TK et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349:2004-13.
35. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003; 25:2487-505.